Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2024-09-13
DOI
https://doi.org/10.1016/j.vaccine.2024.126273
Citations
3
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
1.16
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Arangassery Rosemary Bastian, Benoît Callendret, Esther Heijnen, Edmund Omoruyi et al.
3 citations
Vaccine
Respiratory viral infections research
1.16
article

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Arangassery Rosemary Bastian, Benoît Callendret, Esther Heijnen, Edmund Omoruyi, Jeffrey B. Rosen, Roy van Heesbeen, Christy Comeaux
article en
3 citations

Abstract

No abstract available for this paper.
VaccineVol. 42(26)
Janssen (Belgium) (BE), Alliance for Multispecialty Research (United States) (US), Janssen (Netherlands) (NL)
Good health and well-being
Openalex Percentile: Top 20%
Respiratory viral infections research
1.16
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.